ClinicalTrials.gg
RecruitingNCT04447053Updated Jun 22, 2023

Sequential Belimumab and T-cell Based Therapy in SLE

A Phase 4 interventional study of Belimumab Injection [Benlysta] in Systemic Lupus Erythematosus, sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by National University Hospital, Singapore · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Planned enrollment
19th of 36
80 · median 81
Started
2021
with 3 others
Phase 4
10 of 36
2 open now
Registered
26th of 36
by date
Lead sponsor
1 of 36
National University Hospital, Singapore

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 19th largest by planned enrollment, is one of 4 that started in 2021, is one of 10 in phase 4, and was the 26th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

Systemic lupus erythematosus (SLE) is a disease in which the immune system (the bodily system that fights infection) attacks the body's own cells and tissues, causing inflammation and organ damage if not promptly and appropriately managed. Autoantibodies (specific proteins produced by the immune system which participate in attacking self tissues and organs) are the hallmarks of SLE which are produced by a specific type of white blood cells called B cells. Belimumab (Benlysta®) is a monoclonal antibody against the B cells by blocking the action of BLyS, a protein that prolongs the longevity and enhances the functions of B cells and is found to be elevated in patients with SLE, was approved by the FDA to treat patients with SLE. This study aims to study the effects of Belimumab on T cells, another specific type of white blood cells which also play a crucial role in SLE, in patients with SLE. In this trial, 80 adult patients with SLE will be recruited, 40 of them will be assigned to receive intravenous (IV) Belimumab with standard of care therapy (SOC), and 40 to receive SOC only. After 48 weeks of exposure to Belimumab + SOC and SOC alone, the phenotype and functions of T cells will be studied and compared.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 21
  2. Able to understand the details of the trial and willing to give written and comply with the requirements of the study protocol.
  3. Patients who fulfill the classification criteria (SLICC 2012 or ACR 1997) for SLE and have active disease (SELENA-SLEDAI ≥ 6).
  4. Patients whose sera are positive for ANA (titre ≥ 1:80) or anti-dsDNA (>100U/L based on NUH standard laboratory cut-off).
  5. Patients who are on stable dose of prednisolone (0-40mg/day) and/or non-steroidal anti-inflammatory, antimalarial or drugs for at least 30 days before first study dose.
  6. Females of and non-sterilized males with female partners of child-bearing potential may participate this trial only if they use a reliable means of .
  7. Females of child-bearing potential must have a negative serum pregnancy test within three weeks prior to baseline.

Exclusion criteria

Exclusion Criteria:

  1. They have severe active nephritis and/or active CNS lupus and/or other diseases e.g. RA, mixed connective tissue disease, scleroderma, dermatomyositis and polymyositis.
  2. They are pregnant.
  3. They have had previous treatment with any B-cell and T-cell targeted biologic therapy, intravenous (IV) cyclophosphamide within 6 months of enrolment, intravenous immunoglobulins or prednisolone (>100mg/day) within 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Belimumab + SOC

    Patients will be administered Belimumab, 10mg/kg, intravenously (IV) (together with SOC) in 1 hour on days 0, 14, and 28, and then every 28 days (4 weeks) until week 48.

    Drug: Belimumab Injection [Benlysta]

  • No intervention
    SOC only

    Patients will receive SOC based on the discretion of attending physicians in accordance with the clinical disease manifestations of SLE and NUH practice of the treatment of SLE.

Interventions

  • DrugBelimumabStudies of BelimumabBelimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.

06

What researchers measure

Primary outcomes

  1. Comparing the ratio of Treg/Teff in Belimumab + SOC arm with SOC-only arm

    The enumeration of T-cell subsets by multi-color flow cytometry including Th1 (CD4+Tbet+), Th2 (CD4+GATA3+), Th17 (CD4+RoRgamat+) and Treg (CD4+CD25+FoxP3+) cells, as well as CD19+CD20+ B cells after staining with respective fluorescent-conjugated antibodies.

    Time frame: Baseline, week 4, week 12, week 24, week 36, week 48 and week 60

  2. Identifying and comparing the TCR sequence of the variable regions (CDR1, CDR2 and CDR3) and their RNA expression profile before and after 48 weeks of Belimumab therapy

    TCR sequencing and RNA expression with the use of the state-of-the-art 10x Genomic nano-droplet technology.

    Time frame: up to week 48

Secondary outcomes

  1. To compare the numeric difference in other T cell subsets (Th1, Th2 and Th17) between the 2 arms

    The enumeration of T-cell subsets by multi-color flow cytometry.

    Time frame: Baseline, week 4, week 12, week 24, week 36, week 48 and week 60

  2. To compare the potential improvement of cognitive function between the 2 arms

    The use of the computerized Automated Neuropsychological Assessment Matrix (ANAM) which serves as an initial screening tool to pick up subtle cognitive dysfunction in healthy populations and serial assessments to track the progress of cognitive dysfunction in SLE patients over time.

    Time frame: Baseline and week 52

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for May 2025, 42 months after the start.

Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's planned 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 25, 2020
StartActual
Nov 8, 2021
Primary completionEst.
May 20, 2025
CompletionEst.
May 20, 2025
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04447053
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 25, 2020
Start date
Nov 8, 2021
Primary completion
May 20, 2025 (estimated)
Completion
May 20, 2025 (estimated)
Last update
Jun 22, 2023

Study contacts

Anselm Mak
Contact
mdcam@nsu.edu.sg
+6567722598
Nien Yee Kow
Contact
mdckown@nus.edu.sg
+6566015194
Anselm Mak
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion